Nouvelle déclaration d'incident
No de la demande: 2023-0818
Numéro de référence du titulaire d'homologation: 2023-US-001675
Nom du titulaire (nom légal complet, aucune abbréviation): Wellmark International
Adresse: 100 Stone Road West, Suite 111
Ville: Guelph
État: Ontario
Pays: Canada
Code postal /Zip: N1G 5L3
Incident chez l'humain
Pays: UNITED STATES
État: CALIFORNIA
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 2724-454
Nom du produit: Zodiac Fleatrol Fogger
Autre (préciser)
AerosolNon
Inconnu
Personne affectée
Sexe: Femme
Âge: >19 <=64 yrs / >19 <=64 ans
Système
Unknown / Inconnu
Oui
Non
Non professionnel
Inconnu
Inconnu
Unknown / Inconnu
Unknown / Inconnu
On approximately 01 Jan 2020, a person with no known concomitant medical conditions, was possibly exposed to an unknown amount of Zodiac Fleatrol Fogger via an unknown route. No specific exposure was described the product was purchased on approximately 01 Jan 2020 and placed on a shelf in the home for storage. On approximately 01 Jan 2022, the person developed decreased vision and an unspecified respiratory problem. The person was evaluated by a physician and prescribed eyeglasses. No other treatments were specified. On approximately 01 Oct 2022, her vision continued to worsen. The person was re-evaluated by a physician and her eyeglass prescription was adjusted. No other treatments were specified. On 23 Jan 2023, the person noticed the product on the shelf and stated that it was moist and possibly leaking. No specific exposure was reported. The vision changes persist. No further information was received.
Majeure
Assessment: Given the described exposure the signs and symptoms are not likely correlated with the product. A temporal relationship does not exist as there was no known ocular exposure to the product and symptoms started approximately two years after the product was stored in the house. The pharmacologic/toxicologic picture does not fit with the described possible exposure to the product and all other differential diagnoses have not been ruled out and should be explored. The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.